← All trials

NCT03188185

Phase 3Interventional

Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.

View on ClinicalTrials.gov ↗

Timeline

Start date
Jun 12, 2017
Primary completion
Feb 26, 2020
Completion date
Mar 5, 2020
First posted
Jun 15, 2017
Last posted
Apr 8, 2021
Enrollment
278
Arms / groups
2 / —
Source
AACT · ctgov ingestion

Sponsors

Drugs studied

Indications studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.